AstraZeneca and Cancer Research UK (CRUK) have announced that they will work together to open a new research centre in the UK, applying CRISPR and other functional genomics technologies to develop new cancer drugs. Specifically, the centre will study how genes and proteins interact with each other in cancer cells, and create disease models using genome-altering technologies based on this.
The centre, based in the University of Cambridge and operated through CRUK’s Therapeutic Discovery Laboratories, is intended to serve as a collaborative base for academics to focus on translational research and assessing new drug combinations, speeding up the development of new treatments.
The researchers will own all outputs from their projects, with no associated option rights, though both CRUK and AstraZeneca have equal access to the centre’s screening capacity. Joint projects will be identified on a case-by-case basis by mutual need.